Background--SERCA2a gene transfer (GT) improves mechano-electrical function in animal models of nonischemic heart failure Whether SERCA2a GT reverses pre-established remodeling at an advanced stage of ischemic heart failure is unclear. We sought to uncover the electrophysiological effects of adeno-associated virus serotype 1.SERCA2a GT following myocardial infarction (MI).
M yocardial infarction (MI) is a primary cause of advanced heart failure (HF) and a major public health epidemic. Patients with post-MI HF exhibit a 5-year mortality rate of >40%. Of note, malignant ventricular tachycardia and fibrillation (VT/VF) account for %50% of these deaths.
Unfortunately, conventional therapies for arrhythmias that target sarcolemmal ion channels have often exacerbated rather than improved outcomes in this high-risk patient population, 1, 2 highlighting the need for novel approaches.
One such approach is the use of cardiac gene therapy to restore the expression of calcium (Ca 2+ ) cycling proteins, such as the sarco/endoplasmatic reticulum Ca 2+ -ATPase 2a (SERCA2a), in an effort to improve mechano-electrical function. Following proof-of-principal studies in rodents, preclinical investigation using adeno-associated virus serotype 1 (AAV1)-mediated SERCA2a gene transfer provided clear benefits in nonischemic HF secondary to either volume overloading in pigs 3 or tachycardia pacing in sheep. 4, 5 The utility of this therapy for reversing pre-established cardiac dysfunction when delivered at an advanced stage of ischemic HF caused by chronic MI is unknown, as most studies focused on prevention rather than reversal of cardiac dysfunction. Indeed, this issue is especially important, considering the disappointing outcome of the CUPID 2 (Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease Phase 2) trial. 6 In addition to predisposing to heart failure, MI is a major risk factor for malignant ventricular arrhythmias, which are estimated to account for %50% of deaths following MI. A key question is whether accelerating intracellular Ca 2+ cycling using SERCA2a gene therapy suppresses or promotes post-MI arrhythmias. In rodents, SERCA2a overexpression ameliorated triggered activity by decreasing ryanodine receptor-mediated Ca 2+ leak. 7 However, unlike in rodents, post-MI arrhythmias in large animals and humans require an adverse electrophysiological substrate that is capable of converting Ca 2+ -mediated triggers to sustained VT/VF. The goal of the present study was to investigate the electrophysiological effects of SERCA2a gene therapy when delivered at an advanced stage of ischemic HF caused by chronic MI. The experimental protocol was designed to mimic the clinical scenario of HF treatment by cardiac gene therapy as was the case in CUPID 1 and CUPID 2. We determined the mechanism underlying the electrophysiological effects of SERCA2a gene therapy and their putative relationship to altered mechanical function in this clinically relevant large-animal model of ischemic HF.
Methods
All data, analytic methods, and study materials have been provided within the article.
Animal Protocols
All experimental procedures complied with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Protocols were approved by the Institutional Animal Care and Use Committee of the Icahn School of Medicine at Mount Sinai. A detailed time-line of the experimental protocol highlighting the timing of the major procedures is shown in Figure S1 . Female Yorkshire pigs were premedicated using intramuscular Telazol (8.0 mg/kg, Fort Dodge, IA). After undergoing placement of an intravenous line, animals were intubated and ventilated with 40% oxygen. General anesthesia was maintained with intravenous propofol (8-10 mg/kg per h) throughout the procedure. Continuous monitoring with an intravenous saline infusion was maintained for a period of 30 minutes to stabilize hemodynamic status. All animals underwent echocardiographic assessment, followed by hemodynamic measurements. All pigs were subjected to extensive anterior MI (procedure described below) and cage-housed for 1 month to develop chronic HF with marked left ventricular (LV) dysfunction compared with control pigs as we have previous reported. 8 Animal sera were collected at the time of MI to screen for neutralizing antibodies against AAV1. 9 Only animals with neutralizing antibody titer of <1/2 qualified for AAV1.SERCA2a treatment. Cardiac performance was evaluated at 1 month after MI and pigs received either 3910 12 vg AAV1.SERCA2a (MI+SERCA2a, N=12) or saline injection (MI, N=14). Two months after the injection, 6-lead ECGs were recorded and cardiac performance was re-evaluated. In a subset of MI (N=8) and MI+SERCA2a (N=8) pigs, dobutamine stress testing was performed for evaluation of contractile reserve and in vivo arrhythmia risk before euthanizing of the animals.
Myocardial Infarction
Boluses of atropine (0.05 mg/kg) and amiodarone (1-3 mg/ kg) were administered intravenously or intramuscularly before MI creation. A 1000-mL saline bag mixed with atropine (0.1 mg/kg), amiodarone (3 mg/kg), and potassium acetate (20 mEq) was continuously infused at a rate of 300 mL/h for the duration of the procedure. A 7-Fr hockey-stick catheter (Cordis) was advanced into the left coronary artery. A 0.014-inch guide wire (Abbott, Park, IL) was advanced into the left anterior descending artery and a 4.0-mm VOYAGER over-thewire balloon (Abbott) was advanced to the proximal end of the coronary artery. The balloon was then inflated to 3 to 4 atm for 120 minutes to interrupt blood flow ( Figure S1B ) followed by deflation to induce reperfusion. Intramuscular injections of nitroglycerine and furosemide were then administered. Intravenous infusion of saline with amiodarone, atropine, and potassium acetate was adjusted to 50 mL/h and maintained overnight. Animals were returned to their cages and examined daily for signs of pain or distress. Twenty-six pigs that underwent the MI procedure were randomized to receive intracoronary injection of either AAV1.SERCA2a (N=12) or
Clinical Perspective
What Is New?
• We demonstrate that SERCA2a gene therapy in pigs following anterior wall myocardial infarction exerts a primary effect on excitability that is fully independent of a change in mechanical function.
• SERCA2a gene therapy increases myocardial conduction reserve, likely by preventing CAMKII activation in this clinically relevant large-animal model of chronic myocardial infarction.
What Are the Clinical Implications?
• Since many conventional therapies for heart failure-related arrhythmias that target sarcolemmal ion channels are fraught with pro-arrhythmic effects, there is a major unmet need for developing novel approaches that are both effective and safe.
• Our findings highlight the safety and potential utility of targeting defective intracellular calcium using a gene therapy approach for improving conduction and ameliorating arrhythmias.
saline (N=14). The size of the anterior infarct was comparable in MI and MI+SERCA2a pigs (Figure S1C 
Intracoronary SERCA2a Gene Delivery
A total of 12 pigs underwent SERCA2a gene transfer (MI+SERCA2a) and 14 pigs were given saline injection (MI).
Following hemodynamic measurements at the 1-month timepoint, nitroglycerin (1 lg/kg per min) was administered through an intravenous route until the end of the injection procedure. The left coronary artery was cannulated with a 5-Fr hockey stick catheter (CordisVista Brite Tip; Miami, FL). Two 0.014-inch coronary guide wires (Abbott HI-TORQUE ADVANCE, Santa Clara, CA) were introduced into the left anterior descending and left circumflex coronary arteries to fix the position of the catheter. 11 A 15-mL bolus of the virus or saline solution diluted 1:1 in blood was infused into the proximal part of the left main coronary artery at 1 mL/min followed by a 5-mL flush of saline/blood mixture at the same flow rate. Similarly, a 5-mL bolus of virus or saline solution mixed 1:1 in blood was infused into the right coronary artery at 1 mL/min followed by a 5-mL flush. We have previously validated the use of this approach in this pig model for restoring SERCA2a expression. 12 As shown in Figure S1D , myocardial SERCA2a expression was significantly higher in AAV1.SERCA2a-treated (MI+SERCA2a) versus untreated (MI) pigs.
In Vivo ECG Analysis
Six-lead ECGs were recorded at the 3-month time-point from control (N=11), MI (N=14), and MI+SERCA2a (N=10) pigs. Baseline (before dobutamine) ECG parameters were measured manually from 7-s ECG epochs by a clinical electrophysiologist who was blinded to the group. QT-interval duration was corrected for heart rate using the Bazzett and Fredericia formulas. An animal was classified as having R 0 waves if 1 or more ECG leads displayed a secondary R wave consistently throughout the 7-s ECG epoch.
Assessment of Cardiac Performance
A Philips iE-33 ultrasound system (Philips Medical Systems, Andover, MA) was used to acquire echocardiographic data with a multifrequency imaging transducer from MI (N=14) and MI+SERCA2a (N=12) pigs. Complete Doppler transthoracic echocardiographic studies were performed. Images were recorded during end-expiratory breath-hold in the standard LV apical view. Three-dimensional echocardiography data sets were acquired from 4 to 7 consecutive cardiac cycles using the R-wave-triggered mode. An average of 3 data sets were acquired per pig. Postacquisition image analyses were performed using Q-lab (Phillips Medical Systems) by blinded investigators. LV volumes were calculated using 3-dimensional full-volume algorithms including a semi-automated border detection system. The endocardial detection accuracy was manually monitored and optimized. Dobutamine stress (2.5 lg/kg per min) testing was performed before euthanizing at the terminal 3-month time-point in MI (N=8) and MI+SERCA2a (N=8) pigs. To achieve sufficient loading, pigs were treated with dobutamine for 15 minutes followed by continuous in vivo ECG monitoring (3-lead ECG) for an additional 5 minutes during dobutamine challenge. Highfidelity pressure-volume analysis in response to preload reduction and 3-dimensional echocardiography were performed before and after infusion with dobutamine for 20 minutes. In vivo arrhythmias in response to the dobutamine stress test were assessed by generating an arrhythmia score for each pig as follows: 0: normal sinus rhythm; 1: <5 premature ventricular beats; 2: 5 to 10 premature ventricular beats; 3: 11 to 20 premature ventricular beats; 4: >20 premature ventricular beats or 1 episode of nonsustained VT of ≤5 beats; 5: 1 or more episodes of VT lasting >5 beats, or/ and multiple episodes of nonsustained VT.
Protein and mRNA Expression Using Western Blot and Quantitative Polymerase Chain Reaction
Frozen tissues from the infarct border of MI (N=6) and MI+SERCA2a (N=5) pigs or a comparable location from noninfarcted control pigs (N=6) were homogenized in RIPA buffer containing protease inhibitor cocktail (Roche) and 20 mmol/L N-ethylmaleimide (Sigma-Aldrich) using the MP homogenate system (FastPrep homogenizer). The insoluble portion was removed by centrifugation at 30 000g for 20 minutes. For immunoblotting, cardiac proteins (10-50 lg) were separated by SDS-PAGE, transferred onto a nitrocellulose membrane (Bio-Rad), and probed with antibodies against GAPDH (Sigma-Aldrich), Nav1.5 (Alomone ASC-005), Cx43 (Sigma C6219), and phosphorylated CAMKII (pierce MA1-047). Blots were developed with Super Signal West Pico (Pierce). Protein band densities were quantified using Image J software (NIH). Total RNAs from tissue were isolated with RNeasy Isolation kit (Qiagen) and the cDNAs were synthesized from a RTreaction using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative polymerase chain reactions (PCR) were performed on a real-time PCR system (Applied Biosystems) with SYBR Green PCR Master Mix (BioRad). The following primer sets were used to detect relative gene expression:
In parallel, 1-step reverse transcription PCR (Qiagen) was performed to confirm the specificity of PCR products by gel electrophoresis.
Histology
Formalin-fixed tissue blocks from control, MI, and MI+S-ERCA2a myocardium were embedded in paraffin, sectioned (7 lm), mounted, and stained with picro-sirius red for assessing fibrosis. Quantification was performed on 7 control, 7 MI, and 10 MI+SERCA2a pigs (2-6 images per pig).
Optical Action Potential Mapping in Porcine Wedge Preparations
We previously developed the technique of transmural optical action potential (AP) mapping in arterially perfused canine and porcine wedge preparations. [13] [14] [15] [16] This technique has been extensively used by others in wedges from explanted human hearts. [17] [18] [19] [20] [21] [22] Briefly, wedges of porcine myocardium were dissected from the mid apico-basal region adjacent to the anterior infarct, a region known to support post-MI arrhythmias. Wedges were arterially perfused via a secondary branch of the high lateral or posterolateral left circumflex coronary artery and optical mapping was performed using the voltage-sensitive dye, di-4-ANEPPS. [13] [14] [15] [16] 23 Porcine wedge preparations were isolated from control (N=8 pigs, n=11 wedges), MI (N=5 pigs, n=10 wedges), and MI+SERCA2a (N=5 pigs, n=10 wedges) animals. Wedges were paced from the endocardium at a wide range of pacing rates (1.0-5.0 Hz in 0. 
Statistical Analysis
N refers to the number of pigs and n to the number of wedges. Hemodynamic measurements and ECG parameters (performed in pigs) are expressed as meanAESD. Electrophysiological measurements (performed in wedges) are expressed as meanAESEM. Differences between groups were evaluated by v 2 testing for discrete variables. For continuous variables, the unpaired t test was used to compare differences between 2 groups and for multiple-comparisons 1-way ANOVA followed by Tukey test was performed. P<0.05 was considered statistically significant.
Results

SERCA2a Gene Therapy Alters In Vivo ECG Parameters in MI Pigs
Before euthanization at the terminal 3-month time-point, in vivo 6-lead ECG parameters were compared in control, MI, ECG parameters of evaluated animals obtained 3 months after MI. Data are presented as meanAESD. bpm indicates beats per minute; HR, heart rate; MI, myocardial infarction; QT c † , corrected QT duration calculated using the Bazett formula; QT c ‡ , corrected QT duration calculated using the Fredericia formula. *P<0.05 vs control using ANOVA followed by Tukey's test. and MI+SERCA2a pigs. As shown in Table 1 , PR, QT, QT c , and average heart rate were similar among groups (P=NS). In contrast, MI pigs exhibited a prolonged (by 34%, P<0.05) QRS duration and a tendency towards altered QRS morphology ( Figure 1A and 1B) . Specifically, we found increased presence of R 0 waves on the 6-lead ECG recordings in MI pigs ( Figure 1C ). These ECG changes were unique to the untreated MI group as they were not present in MI+SERCA2a or control pigs. Further comparison of QRS duration in untreated and SERCA2a-treated MI pigs that exhibited elevated in vivo heart rate (70-100 beats per minute) revealed significantly shorter duration in the latter compared with the former group ( Figure 2A ). As such, in vivo ECG analysis pointed to a potential role for SERCA2a gene therapy in modifying global cardiac conduction in post-MI pigs. To gain insight into potential differences in susceptibility to arrhythmias, we quantified the arrhythmia score in response to dobutamine stress testing in MI and MI+SERCA2a pigs. As shown in Figure 2B , the arrhythmia score index reflecting the frequency and complexity of in vivo arrhythmic activity was significantly (P<0.05) reduced in MI+SERCA2a compared with untreated+++ MI pigs.
SERCA2a Gene Therapy Alters the Electrophysiological Substrate
Guided by the in vivo ECG findings, we proceeded to investigate the tissue-level electrophysiological substrate using high-resolution optical AP mapping in ex vivo perfused wedge preparations from control, MI, and MI+SERCA2a hearts. Consistent with the QT and QT c interval durations Figure S2A ). Moreover, quantification of transmural action potential duration heterogeneity as indexed by the range and SD of action potential duration 80 values across the ventricular wall did not reveal significant differences among groups (Figure S1B and S1C) .
Instead, we uncovered a major unexpected effect of SERCA2a gene therapy on myocardial conduction, particularly during rapid pacing. Figure 3 shows the rate-dependent adaptation of CV and normalized AP upstroke velocity in control, MI, and MI+SERCA2a preparations. At a basal pacing cycle length of 1000 ms, which approximates the in vivo heart rate of pigs, conduction velocity (CV) in untreated and SERCA2a-treated preparations were comparably reduced compared with their control counterparts ( Figure 3A) . In contrast, differences in average CV between MI and MI+S-ERCA2a emerged at pacing cycle length of 250 ms ( Figure 3A) . Analysis of the rate dependence of the normalized upstroke velocity revealed a greater decrease in untreated MI compared with control preparations. Remarkably, SERCA2a gene therapy fully reversed the rate-dependent decrease in this metric of excitability in MI+SERCA2a ( Figure 3B ).
We therefore surmised that there are intrinsic differences in myocardial conduction reserve between the untreated (MI) and SERCA2a-treated (MI+SERCA2a) groups. Shown in Figure 4A are depolarization isochrone maps recorded from representative MI and MI+SERCA2a preparations that illustrate the crowding of isochrones lines in MI but not MI+SERCA2a preparations as the pacing rate was elevated from 1.0 to 4.0 Hz. On average, when normalized CV ( Figure 4B ) and AP upstroke velocity ( Figure 4C , dF/dt max ) were plotted as a function of pacing rate (Hz), a linear relationship was observed with a significantly greater negative slope for MI compared with MI+SERCA2a (Figure 4D and 4E ) indicative of greater conduction reserve in the latter compared with the former group at elevated heart rates.
SERCA2a Gene Therapy Suppresses PacingInduced Arrhythmias Ex Vivo
Based on our findings of increased myocardial conduction reserve at rapid heart rates in MI+SERCA2a compared with MI hearts, we hypothesized that SERCA2a gene therapy may elicit a protective anti-arrhythmic effect specifically during challenge with rapid pacing. To address this, arterially perfused porcine wedge preparations from control, MI, and MI+SERCA2a pigs were subjected to steady-state pacing at progressively faster rates up to 5.0 Hz or the induction of VT/ VF ( Figure 5A ). Indeed, while none of the control preparations exhibited pacing-induced VT/VF, 80% of MI pigs were susceptible to VT/VF. SERCA2a gene therapy suppressed VT/VF propensity to only 20% of MI+SERCA2a pig hearts ( Figure 5B ).
Effect of SERCA2a Gene Therapy on Hemodynamic Function
We hypothesized that the beneficial electrophysiological effects of SERCA2a gene therapy may be related to regression Figure 3 . A, PCL-dependent adaptation of CV plotted in Ctrl (n=7 wedges, N=5 pigs), MI (n=8 wedges, N=4 pigs), and MI+SERCA2a (n=8 wedges, N=5 pigs) preparations. B, PCLdependent adaptation of the normalized AP upstroke velocity relative to that at PCL 1000 ms in preparations from Ctrl (n=7, N=5), MI (n=8, N=4), and MI+SERCA2a (n=8, N=5) animals. AP indicates action potential; CV, conduction velocity; Ctrl, control; MI, myocardial infarction; PCL, pacing cycle length.
of HF and improvements in overall mechanical function. We therefore performed a systematic evaluation of hemodynamic properties using invasive pressure-volume analyses and noninvasive echocardiographic measurements. LV volumetric parameters were evaluated by 3-dimensional echocardiography. Surprisingly, we found no evidence of improved cardiac function either by echocardiography (Table 2) or invasive pressure volume analyses ( Table 3 ). As such, improved electrophysiological parameters were unlikely related to mechanical function. We also tested the response of a subset of MI and MI+SERCA2a pigs (N=6 per group) to dobutamine (2.5 lg/kg per minute) challenge as a measure of contractile reserve. As shown in Figure 6 , invasive and noninvasive hemodynamic measurements using pressure volume loop analyses and 3-dimensional echocardiography revealed no differences between MI and MI+SERCA2a pigs before and after dobutamine challenge as end diastolic volume relationship, end systolic pressure volume relationship, preload recruitable stroke work, left ventricular ejection fraction, end diastolic volume, and longitudinal strain were comparable (P=NS for all indices, Figure 6 ). from Ctrl, MI, and MI+SERCA2a hearts at progressively increasing pacing rates. Arterially perfused wedges from MI but not MI+SERCA2a or Ctrl animals were prone to VT/VF during challenge with rapid pacing. B, Propensity for VT/VF of Ctrl (N=8), MI (N=5) and MI+SERCA2a (N=5) pigs. A given heart was considered arrhythmia-prone if at least 1 preparation from that heart exhibited pacing-induced VT/VF that was sustained. *P<0.05 vs Ctrl. Ctrl indicates control; MI, myocardial infarction; VT/VF, ventricular tachycardia and fibrillation.
Effects of SERCA2a Gene Therapy on the Molecular Determinants of Excitability
Since the favorable impact of SERCA2a gene therapy on myocardial conduction in MI could not be explained by improved hemodynamic status or myocardial contractile reserve assessed by in vivo dobutamine testing, we surmised that there may be a primary effect on the molecular correlates that dictate myocardial conduction. To address this, we examined the expression of the main ventricular gap junction protein Cx43 because of its importance to AP propagation. As shown in Figure 7 , total Cx43 expression was decreased by %50% in MI compared with control hearts. Despite a trend towards restored expression of total Cx43 by SERCA2a gene therapy, differences between MI and MI+SERCA2a were not statistically significant. We also measured the dephosphorylated (Po) component of Cx43, which underwent marked upregulation (by >4-fold) in MI compared with control pigs (Figure 7 ). Increased expression of this dephosphorylated Cx43 component was also not reversed by AAV1.SERCA2a gene therapy (P=0.177 between MI and MI+SERCA2a) (Figure 7) .
A hallmark of adverse structural remodeling in ischemic heart disease is the deposition of fibrotic lesions that disrupt myocardial conduction and promote conduction-dependent arrhythmias. We measured the expression of multiple profibrotic markers including connective tissue growth factor (CTGF), transforming growth factor-b (TGF-b), Collagen type 1, alpha 1 (Col1A1), Collagen type 3, alpha 1 (Col3A1), and SMAD3 in MI and MI+SERCA2a hearts relative to control. As shown in Figure 8A , CTGF, TGF-b, and Col1A1 mRNA expression was increased by %3-fold (P<0.01) in MI hearts compared with control. Remarkably, SERCA2a gene therapy fully reversed these changes in profibrosis markers. To determine whether differences in the mRNA expression of profibrotic markers were associated with actual changes in fibrotic content, we determined the extent of fibrosis in histological sections that were stained with picrosirius red ( Figure 8B ). While samples from untreated MI pigs exhibited a marked rise in picrosirius red staining compared with control, treatment of MI pigs with AAV1-SERCA2a failed to ameliorate this change. Finally, we found that Nav1.5 expression was comparable across all groups (Figure 9A) , discounting a change in the expression of the pore-forming alpha subunit of the sodium channel in the functional changes that we observed. Therefore, we surmised that the differences in the rate dependence of myocardial conduction and excitability are likely related to differences in Na channel activity rather than expression. In recent years, studies have focused on the intricate regulation of Nav1.5 activity by CaMKII, 24-27 a key calcium-dependent kinase that is activated in MI. In particular, CAMKII activation was shown to modulate Na channel recovery from inactivation. 27 We therefore measured the expression levels of phosphoactive CAMKII (phosphorylated at Thr-287, pCaM-KII) levels in control, MI, and MI+SERCA2a hearts. Relative to control, pCaMKIId protein levels were markedly increased in untreated MI and fully reversed in MI+SERCA2a hearts ( Figure 9B ).
Discussion
Ventricular tachyarrhythmias account for %50% of deaths in patients with chronic MI and ischemic HF. 28 Since many conventional therapies for HF-related arrhythmias that target sarcolemmal ion channels are fraught with pro-arrhythmic effects, there is a major unmet need for developing novel approaches that are both effective and safe. This is particularly urgent for post-MI patients in whom conventional antiarrhythmic drugs such as flecainide and sotalol have increased rather than decreased mortality. 1, 2 Because the extent of mechanical dysfunction is a predictor of adverse arrhythmic events, we hypothesized that improving excitation-contraction coupling, mechanical function, and overall heart failure status by restoring SERCA2a expression by gene transfer may improve electrical remodeling and suppress the incidence of malignant arrhythmias. Despite its success in improving hemodynamic function in animal models, the effective translation of SERCA2a gene therapy to the clinic has faced a major setback as AAV1-SERCA2a gene therapy failed to achieve the preset primary or secondary end points of the CUPID 2 trial. The neutral effects of this therapy in CUPID 2 were likely caused by technical rather than conceptual challenges stemming from inadequate myocardial gene transduction by the chosen gene delivery approach and viral dose. Indeed, very low to absent levels (<10-192 ssDNA copy number/lg human DNA) of transgene DNA were ultimately detected in CUPID 2 patients who underwent left ventricular assist device implantation or cardiac transplantation. As such, failure to achieve robust delivery of the transgene to the myocardium of patients with HF is likely the main culprit for the neutral effects of this clinical trial. The technical limitations that have confounded clinical trials of cardiac gene therapy can be circumvented in animal models in which robust gene delivery can be assured. Therefore, in this study, we were able to address the central question of whether SERCA2a overexpression prevents or provokes arrhythmias in ischemic HF.
To that end, we investigated mechanisms by which SERCA2a gene therapy modulates the electrophysiological substrate and risk of arrhythmias in a clinically relevant pig model of ischemic HF secondary to chronic MI. The major finding is the discovery of an unexpected primary effect of this gene therapy approach on myocardial conduction that is independent of a change in mechanical function. Surprisingly, we found that improved electrophysiological properties by SERCA2a gene therapy could not be explained by differences in hemodynamic function or contractile reserve as assessed by dobutamine testing but rather were caused by direct effects on a molecular target that regulates AP propagation in a rate-dependent manner.
SERCA2a Gene Therapy in Advanced Ischemic HF
The vast majority of previous studies examining the impact of SERCA2a gene therapy on electrophysiological properties in the failing heart were carried out in rodent models in which arrhythmias depend on calcium-mediated triggered activity. In these earlier studies, SERCA2a gene therapy was effective in suppressing triggered activity by reducing SR calcium leak and spontaneous calcium waves. 7 Unlike in rodents, however, complex arrhythmias in humans and large animals require an appropriate electrophysiological substrate that converts calcium-mediated triggers into sustained VT/VF. One study in a guinea pig model of pressure overload hypertrophy demonstrated the ability of SERCA2a gene therapy when applied at the time of aortic banding to suppress repolarization alternans. 29 However, the impact of SERCA2a gene therapy on the electrophysiological substrate in clinically relevant large-animal models of ischemic HF remained unknown. A major advantage of our current experimental design was the administration of SERCA2a gene therapy following preestablishment of LV dysfunction rather than as a preventive measure before its onset. This design was chosen to mimic the clinical scenario of cardiac gene therapy in patients with advanced HF. To our knowledge, this is the first report demonstrating improved myocardial conduction reserve in ischemic HF by a gene therapy approach that targets intracellular calcium cycling.
Effects of SERCA2a Gene Therapy on Myocardial Conduction
Our focus on myocardial conduction was motivated by unexpected in vivo ECG findings in MI and MI+SERCA2a pigs. In particular, we found that SERCA2a gene therapy ameliorates QRS duration prolongation and suppresses the incidence of R 0 waves in MI pigs. These changes arose in the absence of any changes in heart rate, PR, or QT intervals implicating SERCA2a gene therapy in the modulation of global ventricular conduction. Consistent with these observations, Katz et al 30 demonstrated reversal of QRS prolongation by cardiac surgery-mediated SERCA2a overexpression with recirculation delivery in a sheep model of ischemic heart disease. Guided by our in vivo ECG findings, we systematically studied the electrophysiological substrate at the tissue level. Indeed, MI+SERCA2a preparations exhibited relatively preserved CV and AP upstroke velocity at fast compared with basal rates. We proceeded to investigate the putative mechanisms and discounted altered expression of Cx43 or Nav1.5 as major factors in the functional changes that we observed. Moreover, while SERCA2a gene therapy reversed the rise in profibrotic gene expression in MI, these changes did not impact actual fibrosis content in histological sections. The lack of impact of our intracoronary gene delivery approach on fibrosis contrasts with the potent fibrosis-suppressing effect of SERCA2a gene delivery by a molecular cardiac surgery approach with recirculating delivery in a sheep model. 31 Our finding of altered conduction and AP upstroke velocity at fast but not slow rates suggests changes in sodium channel activity rather than expression. CAMKII, a calcium-sensitive kinase that is activated post-MI, regulates Na channel activity in a rate-dependent manner. 24, 25, 27 In particular, CAMKIIdependent phosphorylation of Nav1.5 alters I Na gating by reducing current availability at higher pacing rates. 27 Moreover, transgenic overexpression of CAMKIId promotes QRS prolongation and increases predisposition for VT/VF. 27 Indeed, phosphoactive CAMKII levels were markedly upregulated in our porcine MI model in agreement with previous results in human and canine models of ischemic heart failure. 32 Remarkably, SERCA2a gene therapy in MI pigs reversed the increase in phosphorylated CAMKII levels, likely blunting the rate-dependent reduction in AP upstroke velocity and CV at higher pacing rates. Finally, improved conduction properties at rapid rates in MI+SERCA2a pigs were associated with suppression of arrhythmias. Taken together, our findings support a novel mechanism by which SERCA2a gene therapy can improve electrophysiological function and suppress arrhythmias in chronic MI by increasing myocardial conduction reserve independent of a change in contractile function.
Limitations
Our ex vivo approach for evaluating arrhythmia susceptibility was based on challenge of preparations with fast pacing rates. Indeed, the pacing rates that elicited VT/VF in the wedge preparation do not reflect the typical average heart rates in patients with ischemic HF. Having said that, pacing-induced arrhythmias in the intact heart are likely to be encountered at much slower rates than those in wedge preparations because of their small dimensions. Moreover, closely coupled premature ventricular beats, which are frequently observed in post-MI hearts, are likely to be associated with similar conduction patterns and arrhythmia risk as shown here for rapid pacing. More importantly, our rapid pacing protocol was chosen to mimic the reported in vivo pig heart rates that are generated in response to vigorous exercise. 33 
Conclusion
SERCA2a gene therapy increases myocardial conduction reserve, likely by preventing post-MI CAMKII activation. Our findings suggest a primary effect of SERCA2a gene therapy on myocardial conduction that is independent of mechanical dysfunction.
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